Evidence map›Paper›PMID 42843924›Full record

ArticleJournal for immunotherapy of cancer2026

TCASIA: an integrative atlas linking alternative splicing landscapes for cancer immunotherapy.

Yihao Zhang, Yunzhi Guo, Haitao Wang, Yi Xiong, Minjun Chen, Ying Cai, Xin Li, Jun Wu, Jiaqi Hao, Su-Han Jin and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yihao ZhangDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Yunzhi GuoGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Guangzhou, Guangdong, China.
Haitao WangCenter for Precision Medicine Research and Training, University of Macau Faculty of Health Sciences, Macao, Macao.ORCID http://orcid.org/0000-0001-6910-974X
Yi XiongDepartment of Medical Genetics, Capital Centre for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Minjun ChenDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Ying CaiDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Xin LiDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Jun WuDepartment of Emergency and Critical Disease, Songjiang Research Institute, Shanghai Key Laboratory of Emotions and Affective Disorders, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiaqi HaoDepartment of Neurosurgery, Xiangya Hospital Central South University, Changsha, Hunan, China.
Su-Han JinDepartment of Orthodontics, Stomatological Hospital Affiliated to Zunyi Medical University, Zunyi, China.
Wei ZhangDepartment of Neurosurgery, Xiangya Hospital Central South University, Changsha, Hunan, China.
Luohuan DaiDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada.
Hongwei LiuDepartment of Neurosurgery, Xiangya Hospital Central South University, Changsha, Hunan, China.
Jianfeng LiState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
Jiahui ZhangGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Guangzhou, Guangdong, China.
Markus HechtDepartment of Radiotherapy and Radiation Oncology, Saarland University Medical Center, Homburg, Germany.
Benjamin FreyFAU Profile Center Immunomedicine (FAU I-MED), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0001-6743-3351
Udo S GaiplFAU Profile Center Immunomedicine (FAU I-MED), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Xin ChenDepartment of Emergency and Critical Disease, Songjiang Research Institute, Shanghai Key Laboratory of Emotions and Affective Disorders, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xuejun LiDepartment of Neurosurgery, Xiangya Hospital Central South University, Changsha, Hunan, China jianguo.zhou@zmu.edu.cn lxjneuro@csu.edu.cn wangshx@csu.edu.cn mahuab@163.com.ORCID http://orcid.org/0000-0001-6406-4423
Shixiang WangDepartment of Biomedical Informatics, Central South University, Changsha, China jianguo.zhou@zmu.edu.cn lxjneuro@csu.edu.cn wangshx@csu.edu.cn mahuab@163.com.ORCID http://orcid.org/0000-0001-9855-7357
Hu MaDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China jianguo.zhou@zmu.edu.cn lxjneuro@csu.edu.cn wangshx@csu.edu.cn mahuab@163.com.
Jian-Guo ZhouDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China jianguo.zhou@zmu.edu.cn lxjneuro@csu.edu.cn wangshx@csu.edu.cn mahuab@163.com.ORCID http://orcid.org/0000-0002-5021-3739

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdentifying robust predictive biomarkers for immune checkpoint blockade (ICB) remains a challenge. While alternative splicing (AS) shapes tumor immunity, the lack of large-scale, consensus-based datasets constrains the characterization of ICB-specific splicing landscapes.

methodsWe developed TCASIA (the Cancer Alternative Splicing Immunotherapy Atlas), harmonizing >4000 samples across 29 cohorts. A rigorous "2-out-of-4" multi-algorithm consensus framework (rMATS, MAJIQ, SUPPA2, and SplAdder) with a fuzzy matching strategy was used to establish a high-confidence AS landscape.

resultsTCASIA provides a robust toolkit linking splicing perturbations with clinical phenotypes (response, survival, and immune infiltration). Using this platform, we recapitulated the established

conclusionsTCASIA provides an analytical atlas for investigating splicing-mediated immune evasion and prioritizing isoform-specific candidates for further functional and clinical validation in the context of ICB treatment.

Indexed as

Alternative SplicingImmunotherapyNeoplasmsHumansBiomarkerImmunotherapy

Identifiers

PMID42843924
PMCPMC13646984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.